Metalloproteases and Proteolytic Processing

  • Anthony J. Turner
  • Natalia N. Nalivaeva
Part of the Protein Reviews book series (PRON, volume 13)


Proteolytic enzymes constitute around 2% of the human genome and are involved in all stages of cell and organism development from fertilization through to cell death. In the human genome the major classes of peptidases are represented by cysteine-, serine- and metalloenzymes, which possess a wide spectrum of substrate specificity and physiological functions. The identification of many novel peptidases from genome sequencing programmes has suggested potential new therapeutic targets. In addition, several well characterised peptidases were recently shown to possess new and unexpected biological roles in neuroinflammation, cancer and angiogenesis, cardiovascular diseases and neurodegeneration. This chapter will briefly characterize the main classes of metallopeptidases and their roles in health and disease. Particular attention will be paid to the angiotensin-converting enzyme (ACE), neprilysin (NEP) and adamalysin (ADAM) families of proteases and their pathophysiological roles with a particular emphasis on cancer and neurodegeneration. The roles and mechanisms of protein shedding which primarily involve the ADAMs family of metallopeptidases will be explained using amyloid protein precursor (APP) processing cascades as a well characterized example. The therapeutic significance of modulating (activating or inhibiting) metallopeptidase activity will be a particular focus of this chapter.


Severe Acute Respiratory Syndrome Amyloid Precursor Protein Prion Protein Thrombotic Thrombocytopenic Purpura Severe Acute Respiratory Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Amyloid β-peptide


Angiotensin converting enzyme


APP intracellular domain


Amyloid precursor protein


Endothelin-converting enzyme


Insulysin (insulin-degrading enzyme)


Matrix metalloproteinase


Plasminogen-activator inhibitor


Renin-angiotensin system



We thank the Medical Research Council of Great Britain and Russian Academy of Sciences Programme “Fundamental Sciences to Medicine” for financial support.


  1. Akiyama, H., Shii, K., Yokono, K., et al. (1988). Cellular localization of insulin-degrading enzyme in rat liver using monoclonal antibodies specific for this enzyme. Biochem. Biophys. Res. Commun. 155:914–922.PubMedGoogle Scholar
  2. Alfalah, M., Parkin, E.T., Jacob, R., et al. (2001). A point mutation in the juxtamembrane stalk of human angiotensin I-converting enzyme invokes the action of a distinct secretase. J. Biol. Chem. 276: 21105–21109.PubMedGoogle Scholar
  3. Allinson, T.M., Parkin, E.T., Condon, T.P., et al. (2004). The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur. J. Biochem. 271:2539–2547.PubMedGoogle Scholar
  4. Bachmair, A., Finley, D., Varshavsky, A. (1986). In vivo half-life of a protein is a function of its amino-terminal residue. Science 234:179–186.PubMedGoogle Scholar
  5. Bartz, R., Sun, L.P., Bisel, B., et al. (2008). Spatial separation of Golgi and ER during mitosis protects SREBP from unregulated activation. EMBO J. 27:948–955.PubMedGoogle Scholar
  6. Belyaev, N.D., Nalivaeva, N.N., Makova, N.Z., et al. (2009). Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep. 10:94–100.PubMedGoogle Scholar
  7. Beninga, J., Rock, K.L., Goldberg, A.L. (1998). Interferon-gamma can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J. Biol. Chem. 273:18734–18742.PubMedGoogle Scholar
  8. Bergo, M.O., Gavino, B., Ross, J., et al. (2002). Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc. Natl. Acad. Sci. USA. 99:13049–13054.PubMedGoogle Scholar
  9. Blais, V., Fugère, M., Denault, J.B., et al. (2002). Processing of proendothelin-1 by members of the subtilisin-like pro-protein convertase family. FEBS Lett. 524:43–48.PubMedGoogle Scholar
  10. Bland, N.D., Pinney, J.W., Thomas, J.E., et al. (2008). Bioinformatic analysis of the neprilysin (M13) family of peptidases reveals complex evolutionary and functional relationships. BMC Evol. Biol. 8:16.PubMedGoogle Scholar
  11. Bland, N.D., Robinson, P., Thomas, J.E., et al. (2009). Locomotor and geotactic behavior of Drosophila melanogaster over-expressing neprilysin 2. Peptides 30:571–574.PubMedGoogle Scholar
  12. Bond, J.S., and Beynon, R.J. (1995). The astacin family of metalloendopeptidases. Protein Sci. 4:1247–1261.PubMedGoogle Scholar
  13. Bradshaw, R.A., Yi, L., Walker, K.W. (2004). Methionyl aminopeptidase type 1. In: Barrett, A.J., Rawlings, N.D., Woessner, J.F. (eds) Handbook of Proteolytic Enzymes, 2 edn. Elsevier, London, pp. 911–917.Google Scholar
  14. Bunnett, N.W. (2006). Protease-activated receptors: how proteases signal to cells to cause inflammation and pain. Semin. Thromb. Hemost. 32(Suppl 1):39–48.Google Scholar
  15. Burley, S.K., David, P.R., Taylor, A., et al. (1990). Molecular structure of leucine aminopeptidase at 2.7-Å resolution. Proc. Natl. Acad. Sci. USA. 87:6878–6882.PubMedGoogle Scholar
  16. Caille, I., Allinquant, B., Dupont, E., et al. (2004). Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 131:2173–2181.PubMedGoogle Scholar
  17. Cal, S., Quesada, V., Garabaya, C., et al. (2003). Polyserase-I, a human polyprotease with the ability to generate independent serine protease domains from a single translation product. Proc. Natl. Acad. Sci. USA. 100:9185–9190.PubMedGoogle Scholar
  18. Canet-Aviles, R.M., Anderton, M., Hooper, N.M., et al. (2002). Muscarine enhances soluble amyloid precursor protein secretion in human neuroblastoma SH-SY5Y by a pathway dependent on protein kinase C(α), src-tyrosine kinase and extracellular signal-regulated kinase but not phospholipase C. Brain Res. Mol. Brain Res. 102:62–72.PubMedGoogle Scholar
  19. Cao, X., and Südhof, T.C. (2001). A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293:115–120.PubMedGoogle Scholar
  20. Chen, A.C., and Selkoe, D.J. (2007). Response to: Pardossi-Piquard et al., “Presenilin-dependent transcriptional control of the Aβ-degrading enzyme neprilysin by intracellular domains of βAPP and APLP.” Neuron 53:479–483.PubMedGoogle Scholar
  21. Conti, L., and Cattaneo, E. (2005). Controlling neural stem cell division within the adult subventricular zone: an APPealing job. Trends Neurosci. 28:57–59.PubMedGoogle Scholar
  22. Cottrell, G.S., Hyde, R.J., Lim, J., et al. (2000). Identification of critical residues in the active site of porcine membrane-bound aminopeptidase P. Biochemistry 39:15129–15135.PubMedGoogle Scholar
  23. Cynis, H., Scheel, E., Saido, T.C., et al. (2008). Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-β. Biochemistry 47:7405–7413.PubMedGoogle Scholar
  24. Danilczyk, U., Sarao, R., Remy, C., et al. (2006). Essential role for collectrin in renal amino acid transport. Nature 444:1088–1091.PubMedGoogle Scholar
  25. Delaet, N.G., Robinson, L.A., Wilson, D.M. (2003). Novel inhibitors of procollagen C-terminal proteinase. Part 1: Diamino acid hydroxamates. Bioorg. Med. Chem. Lett. 13:2101–2104.PubMedGoogle Scholar
  26. Dawson, L.A., Maitland, N.J., Turner, A.J., et al. (2004). Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br. J. Cancer 90:1577–1582.PubMedGoogle Scholar
  27. Dumermuth, E., Sterchi, E.E., Jiang, W.P., et al. (1991). The astacin family of metalloendopeptidases. J. Biol. Chem. 266:21381–21385.PubMedGoogle Scholar
  28. Dwivedi, A., Slater, S.C., George, S.J. (2009). MMP-9 and -12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc. Res. 81:178–186.PubMedGoogle Scholar
  29. Edland, S.D. (2004). Insulin-degrading enzyme, apolipoprotein ε, and Alzheimer’s disease. J. Mol. Neurosci. 23:213–217.PubMedGoogle Scholar
  30. Elsässer-Beile, U., Bühler, P., Wolf, P. (2009). Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr. Drug Targets 10:118–125.PubMedGoogle Scholar
  31. Farris, W., Mansourian, S., Chang, Y., et al. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. USA. 100:4162–4167.PubMedGoogle Scholar
  32. Feng, L., Yan, H., Wu, Z., et al. (2007). Structure of a site-2 protease family intramembrane metalloprotease. Science 318:1608–1612.PubMedGoogle Scholar
  33. Fischer, A., Sananbenesi, F., Wang, X., et al. (2007). Recovery of learning and memory is associated with chromatin remodelling. Nature 447:178–182PubMedGoogle Scholar
  34. Fosang, A.J., and Little, C.B. (2008). Drug insight: aggrecanases as therapeutic targets for osteoarthritis. Nat. Clin. Pract. Rheumatol. 4:420–427.PubMedGoogle Scholar
  35. Frottin, F., Martinez, A., Peynot, P. (2006). The proteomics of N-terminal methionine cleavage. Mol. Cell Proteomics 5:2336–2349.PubMedGoogle Scholar
  36. Glenner, G.G., and Wong, C.W. (1984). Alzheimer’s Disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:885–890.PubMedGoogle Scholar
  37. Hagaman, J.R., Moyer, J.S., Bachman, E.S., et al. (1998). Angiotensin-converting enzyme and male fertility. Proc. Natl. Acad. Sci. USA. 95:2552–2557.PubMedGoogle Scholar
  38. Hama, E., and Saido, T.C. (2005). Etiology of sporadic Alzheimer’s disease: somatostatin, neprilysin, and amyloid beta peptide. Med. Hypotheses 65:498–500PubMedGoogle Scholar
  39. Hardy, J.A., and Higgins, G.A. (1992). Alzheimer’s disease: the amyloid cascade hypothesis. Science 256: 184–185.PubMedGoogle Scholar
  40. Hooper, N.M., and Turner, A.J. (2002). The search for α-secretase and its potential as a therapeutic approach to Alzheimer’s disease. Curr. Med. Chem. 9:1107–1119.PubMedGoogle Scholar
  41. Hooper, N.M., Karran, E.H., Turner, A.J. (1997). Membrane protein secretases. Biochem J. 321:265–279.PubMedGoogle Scholar
  42. Hooper, N.M., Keen, J., Pappin, D.J., et al. (1987). Pig kidney angiotensin converting enzyme. Purification and characterization of amphipathic and hydrophilic forms of the enzyme establishes C-terminal anchorage to the plasma membrane. Biochem. J. 247:85–93.PubMedGoogle Scholar
  43. Huang, K.F., Liu, Y.L., Wang, A.H. (2005). Cloning, expression, characterization, and crystallization of a glutaminyl cyclase from human bone marrow: a single zinc metalloenzyme. Protein Expr. Purif. 43:65–72.PubMedGoogle Scholar
  44. Hunt, C.E., and Turner, A.J. (2009). Cell biology, regulation and inhibition of β-secretase (BACE-1). FEBS J. 276:1845–1859.PubMedGoogle Scholar
  45. Huovila, A.P., Turner, A.J., Pelto-Huikko, M. (2005). Shedding light on ADAM metalloproteinases. Trends Biochem. Sci. 30:413–422.PubMedGoogle Scholar
  46. Iwata, N., Tsubuki, S., Takaki, Y., et al. (2000). Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nature Med. 6:143–150.PubMedGoogle Scholar
  47. Jolly-Tornetta, C., and Wolf, B.A. (2000). Protein kinase C regulation of intracellular and cell surface amyloid precursor protein (APP) cleavage in CHO695 cells. Biochemistry 39:15282–15290.PubMedGoogle Scholar
  48. Jones, G.C., and Riley, G.P. (2005). ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res. Ther. 7:160–169.PubMedGoogle Scholar
  49. Kaser, M., Kambacheld, M., Kisters-Woike, B., et al. (2003). Oma1, a novel membrane-bound metallopeptidase in mitochondria with activities overlapping with the m-AAA protease. J. Biol. Chem. 278:46414–46423.PubMedGoogle Scholar
  50. Kerr, M., and Kenny, A.J. (1974). The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem. J. 137:477–488.PubMedGoogle Scholar
  51. Killar, L., White, J., Black, R. (1999). Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann. N Y Acad. Sci. 878:442–452.PubMedGoogle Scholar
  52. Kirkby, N.S., Hadoke, P.W., Bagnall, A.J., et al. (2008). The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br. J. Pharmacol. 153:1105–1119.PubMedGoogle Scholar
  53. Klusák, V., Barinka, C., Plechanovová, A., et al. (2009). Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods. Biochemistry 48:4126–4138.PubMedGoogle Scholar
  54. Kowalczuk, S., Bröer, A., Tietze, N. (2008). A protein complex in the brush-border membrane explains a Hartnup disorder allele. FASEB J. 22:2880–2887.PubMedGoogle Scholar
  55. Lee, M.H., Verma, V., Maskos, K., et al. (2002). The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3. FEBS Lett. 520:102–106.PubMedGoogle Scholar
  56. Leissring, M.A., Lu, A., Condron, M.M., et al. (2003). Kinetics of amyloid β-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J. Biol. Chem. 278:37314–37320.PubMedGoogle Scholar
  57. Leopoldini, M., Russo, N., Toscano, M., et al. (2007). Which one among Zn(II), Co(II), Mn(II), and Fe(II) is the most efficient ion for the methionine aminopeptidase catalyzed reaction? J. Am. Chem. Soc. 129:7776–7784.PubMedGoogle Scholar
  58. Letarte, M., Vera, S., Tran, R., et al. (1988). Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase. J. Exp. Med. 168:1247–1253.PubMedGoogle Scholar
  59. Lichtenthaler, S.F., and Haass, C. (2004). Amyloid at the cutting edge: activation of α-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. J. Clin. Invest. 113:1384–1387.PubMedGoogle Scholar
  60. Luo, Y., Bolon, B., Kahn, S., et al. (2001). Mice deficient in BACE1, the Alzheimer’s b-secretase, have normal phenotype and abolished β–amyloid generation. Nat. Neurosci. 4:231–232.PubMedGoogle Scholar
  61. Maskos, K., Fernandez-Catalan, C., Huber, R., et al. (1998). Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. Proc. Natl. Acad. Sci. USA. 95:3408–3412.PubMedGoogle Scholar
  62. Masters, C.L., Simms, G., Weinman, N.A., et al. (1985). Amyloid plaque core protein in Alzheimer disease and Down Syndrome. Proc. Natl. Acad. Sci. USA. 82:4245–4249.PubMedGoogle Scholar
  63. Matsas, R., Fulcher, I.S., Kenny, A.J., et al. (1983). Substance P and [Leu]enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli. Proc. Natl. Acad. Sci. USA. 80:3111–3115.PubMedGoogle Scholar
  64. Menard, J., and Patchett, A.A. (2001). Angiotensin-converting enzyme inhibitors. Adv. Protein Chem. 56:13–75.PubMedGoogle Scholar
  65. Menchén, L., Marín-Jiménez, I., Arias-Salgado, E.G., et al. (2009). Matrix metalloproteinase 9 is involved in Crohn’s disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Gut 58:920–928.PubMedGoogle Scholar
  66. Mogk, A., Schmidt, R., Bukau, B. (2007). The N-end rule pathway for regulated proteolysis: prokaryotic and eukaryotic strategies. Trends Cell Biol. 17:165–172.PubMedGoogle Scholar
  67. Moura-da-Silva, A.M., Butera, D., Tanjoni, I. (2007). Importance of snake venom metalloproteinases in cell biology: effects on platelets, inflammatory and endothelial cells. Curr. Pharm. Des. 13:2893–2905.PubMedGoogle Scholar
  68. Myara, I., Cosson, C., Moatti, N., et al. (1994). Human kidney prolidase -purification, preincubation properties and immunological reactivity. Int. J. Biochem. 26:207–214.PubMedGoogle Scholar
  69. Nalivaeva, N.N., Fisk, L.R., Belyaev, N.D., et al. (2008). Amyloid-degrading enzymes as therapeutic targets in Alzheimer’s disease. Curr. Alzheimer Res. 5:212–224.PubMedGoogle Scholar
  70. Neurath, H. (1999). Proteolytic enzymes, past and future. Proc. Natl. Acad. Sci. USA. 96:10962–10963.PubMedGoogle Scholar
  71. Oefner, C., D’Arcy, A., Hennig, M., et al. (2000). Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. J. Mol. Biol. 296:341–349.PubMedGoogle Scholar
  72. Orth, P., Reichert, P., Wang, W., et al. (2004). Crystal structure of the catalytic domain of human ADAM33. J. Mol. Biol. 335:129–137.PubMedGoogle Scholar
  73. Papandreou, C.N., Usmani, B., Geng, Y., et al. (1998). Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Med. 4:50–57.PubMedGoogle Scholar
  74. Pardossi-Piquard, R., Petit, A., Kawarai, T., et al. (2005). Presenilin-dependent transcriptional control of the Aβ-degrading enzyme neprilysin by intracellular domains of βAPP and APLP. Neuron 46:541–554.PubMedGoogle Scholar
  75. Parkin, E.T., Watt, N.T., Turner, A.J., et al. (2004). Dual mechanisms for shedding of the cellular prion protein. J. Biol. Chem. 279:11170–11178.PubMedGoogle Scholar
  76. Parvathy, S., Hussain, I., Karran, E.H. (1999). Cleavage of Alzheimer’s amyloid precursor protein by α-secretase occurs at the surface of neuronal cells. Biochemistry 38:9728–9734.PubMedGoogle Scholar
  77. Pendas, A.M., Zhou, Z., Cadinanos, J., et al. (2002). Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat. Genet. 31:94–99.PubMedGoogle Scholar
  78. Postina, R., Schroeder, A., Dewachter, I. (2004). A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 113:1456–1464.PubMedGoogle Scholar
  79. Puente, X.S., Sánchez, L.M., Gutiérrez-Fernández, A., et al. (2005). A genomic view of the complexity of mammalian proteolytic systems. Biochem. Soc. Trans. 33:331–334.PubMedGoogle Scholar
  80. Qing, H., He, G., Ly, P.T., et al. (2008). Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer’s disease mouse models. J. Exp. Med. 205:2781–2789.PubMedGoogle Scholar
  81. Quesada, V., Ordóñez, G.R., Sánchez, L.M., et al., (2009). The Degradome database: mammalian proteases and diseases of proteolysis. Nucleic Acids Res. 37 (Database issue):D239–D243.PubMedGoogle Scholar
  82. Raife, T.J., and Montgomery, R.R. (2000). von Willebrand factor and thrombotic thrombocytopenic purpura. Curr. Opin. Hematol. 7:278–283.PubMedGoogle Scholar
  83. Ravid, T., Hochstrasser, M. (2008). Diversity of degradation signals in the ubiquitin-proteasome system. Nature Rev. Mol. Cell Biol. 9:679–690.Google Scholar
  84. Rella, M., Elliot, J.L., Revett, T.J., et al. (2007). Identification and characterisation of the angiotensin converting enzyme-3 (ACE3). gene: a novel mammalian homologue of ACE. BMC Genomics 8:194.PubMedGoogle Scholar
  85. Rawlings, N.D. and Barrett, A.J. (2004). Intruduction: metallopeptidases and their clans. In: Barrett, A.J., Rawlings, N.D., Woessner, J.F. (eds) Handbook of Proteolytic Enzymes, 2 edn. Elsevier, London, pp. 231–268.Google Scholar
  86. Rice, G.I., Thomas, D.A., Grant, P.J. et al. (2004). Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem. J. 383:45–51.PubMedGoogle Scholar
  87. Rholam, M., and Fahy, C. (2009). Processing of peptide and hormone precursors at the dibasic cleavage sites. Cell Mol. Life Sci. 66:2075–2091PubMedGoogle Scholar
  88. Roques, B.P., Fournié-Zaluski, M.C., Soroca, E., et al. (1980). The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 288:286–288.PubMedGoogle Scholar
  89. Rougeot, C., Messaoudi, M., Hermitte, V., et al. (2003). Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity. Proc. Natl. Acad. Sci. USA. 100:8549–8554.PubMedGoogle Scholar
  90. Saha, R.N., and Pahan, K. (2006). HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ. 13:539–550.PubMedGoogle Scholar
  91. Schiavo, G., Benfenati, F., Poulain, B., et al. (1992). Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359:832–835.PubMedGoogle Scholar
  92. Schilling, S., Zeitschel, U., Hoffmann, T., et al. (2008). Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer’s disease-like pathology. Nature Med. 14:1106–1111.PubMedGoogle Scholar
  93. Schulz, H., Dale, G.E., Karimi-Nejad, Y., et al. (2009). Structure of human endothelin-converting enzyme I complexed with phosphoramidon. J. Mol. Biol. 385:178–187.PubMedGoogle Scholar
  94. Seals, D.F., and Courtneidge, S.A. (2003). The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17:7–30.PubMedGoogle Scholar
  95. Skidgel, R.A., and Erdös, E.G. (1985). Novel activity of human angiotensin I converting enzyme: release of the NH2- and COOH-terminal tripeptides from the luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA. 82:1025–1029.PubMedGoogle Scholar
  96. Skotnicki, J.S., DiGrandi, M.J., Levin, J.I. (2003). Design strategies for the identification of MMP-13 and TACE inhibitors. Curr. Opin. Drug Discov. Devel. 6:742–759.PubMedGoogle Scholar
  97. Stöcker, W., Grams, F., Baumann, U., et al. (1995). The metzincins - topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 4:823–840.PubMedGoogle Scholar
  98. Taylor, D.R., Parkin, E.T., Cocklin, S.L., et al. (2009) Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. J. Biol. Chem. 284(34):22590–22600.PubMedGoogle Scholar
  99. Taylor, C.J., Ireland, D.R., Ballagh, I., et al. (2008). Endogenous secreted amyloid precursor protein-α regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol. Dis. 31:250–260.PubMedGoogle Scholar
  100. Thomas, J.E., Rylett, C.M., Carhan, A., et al. (2005). Drosophila melanogaster NEP2 is a new soluble member of the neprilysin family of endopeptidases with implications for reproduction and renal function. Biochem. J. 386:357–366.PubMedGoogle Scholar
  101. Tipnis, S.R., Hooper, N.M., Hyde, R., et al. (2000). A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275:33238–33243.PubMedGoogle Scholar
  102. Tu, G., Xu, W., Huang, H., et al. (2008). Progress in the development of matrix metalloproteinase inhibitors. Curr. Med. Chem. 15:1388–1395.PubMedGoogle Scholar
  103. Turner, A.J. (2008). Angiotensin-converting enzyme 2: cardioprotective player in the renin-angiotensin system? Hypertension 52:816–817.PubMedGoogle Scholar
  104. Turner, A.J., Isaac, R.E., Coates, D. (2001). The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23:261–269.PubMedGoogle Scholar
  105. Turner, A.J., Fisk, L., Nalivaeva, N.N. (2004). Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. Ann. N Y Acad. Sci. 1035:1–20.PubMedGoogle Scholar
  106. Vaisar, T., Kassim, S.Y., Gomez, I.G., et al. (2009). MMP-9 sheds the β2 integrin subunit (CD18) from macrophages. Mol. Cell Proteomics 8:1044–1060.PubMedGoogle Scholar
  107. van Goor, H., Melenhorst, WB, Turner, A.J., et al. (2009). Adamalysins in biology and disease. J. Pathol. 219(3):277–286.PubMedGoogle Scholar
  108. Van Wart, H.E., and Birkedal-Hansen, H. (1990). The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA. 87:5578–5582.PubMedGoogle Scholar
  109. Watermeyer, J.M., Kröger, W.L., O’Neill, H.G., et al. (2008). Probing the basis of domain-dependent inhibition using novel ketone inhibitors of angiotensin-converting enzyme. Biochemistry 47:5942–5950.PubMedGoogle Scholar
  110. Weihofen, A., and Martoglio, B. (2003). Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. Trends Cell Biol. 13:71–78.PubMedGoogle Scholar
  111. Wisner, A., Dufour, E., Messaoudi, M., et al. (2006). Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc. Natl. Acad. Sci. USA. 103:17979–17984.PubMedGoogle Scholar
  112. Whyteside, A.R., and Turner, A.J. (2008). Human neprilysin-2 (NEP2) and NEP display distinct subcellular localisations and substrate preferences. FEBS Lett. 582:2382–2386.PubMedGoogle Scholar
  113. Willem, M., Garratt, A.N., Novak, B., et al. (2006). Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314:664–666.PubMedGoogle Scholar
  114. Wolfe, M.S. (2007). When loss is gain: reduced presenilin proteolytic function leads to increased Aβ42/Aβ40. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 8:136–140.PubMedGoogle Scholar
  115. Wolfe, M.S. (2009). Intramembrane proteolysis. Chem. Rev. 109:1599–1612.PubMedGoogle Scholar
  116. Yanagisawa, M., Kurihara, H., Kimura, S., et al. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415.PubMedGoogle Scholar
  117. Zelenski, N.G., Rawson, R.B., Brown, M.S., et al. (1999). Membrane topology of S2P, a protein required for intramembranous cleavage of sterol regulatory element-binding proteins. J. Biol. Chem. 274:21973–21980.PubMedGoogle Scholar
  118. Zhang, Y., Xu, J., Levin, J. (2004). Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxa mide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J. Pharmacol. Exp. Ther. 309:348–355.PubMedGoogle Scholar
  119. Zhao, J., Li, L., Leissring, M.A. (2009). Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. Mol. Neurodegener. 4:4.PubMedGoogle Scholar
  120. Zhu, G., Wang, D., Lin, Y.H., et al. (2001). Protein kinase Cε suppresses Aβ production and promotes activation of γ-secretase. Biochem. Biophys. Res. Commun. 285:997–1006.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Institute of Molecular and Cellular BiologyUniversity of LeedsLeedsUK
  2. 2.Institute of Evolutionary Physiology and BiochemistryRASSt.PetersburgRussia

Personalised recommendations